The loose term for collections of planners getting together based on any number of shared characteristics or goals can take many forms and provide a lot of value.
Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.